Author + information
- William W. Parmley, MD, MACC*
- ↵*Reprint requests and correspondence: William W. Parmley, MD, MACC, Editor-in-Chief, Journal of the American College of Cardiology, 415 Judah Street, San Francisco, California 94122
Each year in March at the Publications Committee meeting and the annual editorial meeting of JACCI have the opportunity to report on the status of the Journal.I would like to again share this report with the readers of JACCto keep you apprised. The Journalis healthy, and the number of submissions continues to grow. In the calendar year 2000, the editorial office received 2,452 new manuscripts, or an average of 204 per month. This represents a 2% increase over the submission rate (2,402) for 1999. Over the years the Journalhas maintained a steady increase of 2% to 3% each year, except for significantly higher increases in 1995 (16%), 1998 (16%), and 1999 (12%). In the year 2000 we published 3,919 pages. Subscriptions to the Journalfor the year 2000 totaled 31,900. This has remained relatively stable over the past few years.
The “impact factor” is one marker of how often the Journalis cited. In some universities the relative enthusiasm for promotion requires knowing the impact factor of the journals in which the candidate publishes. Over the years from 1995 to 1999 (the year 2000 data are not yet available), the impact factor has risen from 5.793 to 7.368. This steady growth reflects the fact that as the number of manuscripts has increased, the quality of those accepted has also increased, thus driving up the number of times they are cited (and the impact factor).
In the cardiology market, focus readership scores are a marker of how often the Journalis actually read and thus provide a basis for pharmaceutical companies to place their advertising. JACCcontinues to remain well ahead of its two nearest cardiology journal competitors. For example the relative readership scores for JACCin 2000 were 13,469, and for its two closest competitors, 10,338 and 7,779. Thus, JACCcontinues to have more advertising and advertising revenue than they.
JACChas very strict rules about publishing supplements, in order to avoid the potential for publishing pharmaceutical sponsored symposia, which may have conscious or unconscious bias. The only supplement we published this past year (besides the ACC’s 50th Anniversary Historical Articles) was the NIH sponsored Shock Registry, which was mailed with the September 2000 issue. This will be a standard for this clinical problem for years to come.
We continue to receive large numbers of manuscripts from around the world. In the year 2000, 62% of the submissions to JACCoriginated from outside the U.S. Japan leads the foreign submissions, followed by Germany, Italy, the U.K., Canada, France, and the Netherlands. Six translation editions of JACCcontinue publication: three in Spanish, one in Portuguese (Brazil), one in Italian, and one in Czech. In addition, a new translation of JACCis debuting in Poland.
The clinical content of the Journalhas remained the same. We continue to publish 89% clinical articles and 11% experimental studies (which have direct clinical relevance). Because of the increase in numbers of submissions, our rejection rate increased from 79% to 83% over the past year. I know that this figure is disappointing to many authors, whose manuscripts we must reject on the basis primarily of priority rather than scientific content. The lag time from acceptance to publication was averaging 16 weeks. As the backlog has been reduced recently, we are returning to an 11-to-12-week in-press time.
Traditionally, JACChas had an editorial board of about 100 individuals whose names appear under the masthead of JACCin each issue. Because of the expanding number of manuscripts received, this number will be increased this year to 200, and those accepting will be given stricter guidelines regarding the number of manuscripts to be reviewed. We are especially grateful to them and to all of you who regularly review for JACC.Without the unselfish support of many of you, the work of the Journalwould be impossible.
The tenure of the current editors is rapidly approaching 10 years, and this is the last year we will be receiving manuscripts. The Publications Committee conducted a nationwide search for a replacement editor. To avoid a conflict of interest, I was not part of the selection process. The final three candidates were interviewed by the entire committee in Chicago, and Dr. Anthony DeMaria, Chief of Cardiology at the University of California San Diego, was selected as the new Editor-in-Chief to follow us. He will be an outstanding editor and will clearly take JACCto new heights. Over the past few years we have gradually been moving into the electronic age. JACCis available in its entirety on the web page of Elsevier (Cardiosource), which has been a great resource for searching current and back issues. Cardiosource currently has about 50,000 subscribers, with about 70,000 visitor sessions to the website each month. Additional plans to move further into the electronic age will be implemented by Dr. DeMaria as he takes over the leadership of JACCnext year.
As Editor of JACCthese past 10 years, I have really appreciated the comments and suggestions I have received from a loyal readership. It has been a privilege for all of us here in the San Francisco office of JACCto be involved with the College’s flagship publication. We look forward to watching its continued growth and success in the next 10 years.
- American College of Cardiology